Vanguard Global Advisers
NRXP icon

Vanguard Global Advisers’s NRX Pharmaceuticals NRXP Stock Holding History

Vanguard Global Advisers’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.6K Buy
+5,773
New +$19.1K ﹤0.01% 3279

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Global Advisers's NRXP Position: Q2 2026 in Review

Vanguard Global Advisers opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 5,773 shares worth $23.6K. The stake represents ﹤0.01% of the portfolio and ranks #3279 among its holdings.

46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Vanguard Global Advisers held 5,773 shares of NRX Pharmaceuticals worth $23.6K as of Q2 2026.
  • NRX Pharmaceuticals was a new Vanguard Global Advisers position in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3279 holding.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.